The Alzheimer's Association International Conference (AAIC) 2026 represents the premier annual gathering for Alzheimer's and dementia research. This year's conference featured groundbreaking presentations on disease mechanisms, novel therapeutic approaches, biomarker advances, and prevention strategies. The scientific program encompassed over 2,000 presentations across multiple tracks, attracting researchers, clinicians, and industry partners from around the world.
Conference Highlights
Major Research Themes
...
Overview
Mermaid diagram (expand to render)
The Alzheimer's Association International Conference (AAIC) 2026 represents the premier annual gathering for Alzheimer's and dementia research. This year's conference featured groundbreaking presentations on disease mechanisms, novel therapeutic approaches, biomarker advances, and prevention strategies. The scientific program encompassed over 2,000 presentations across multiple tracks, attracting researchers, clinicians, and industry partners from around the world.
Conference Highlights
Major Research Themes
The 2026 conference emphasized several key research areas:
Amyloid and Tau Biology: New insights into amyloid precursor protein (APP) processing, tau phosphorylation mechanisms, and propagation pathways
Microglial Biology: TREM2 variants, DAM (disease-associated microglia) phenotypes, and neuroimmune crosstalk
Biomarker Advances: Blood-based biomarkers (p-tau217, p-tau181,NfL), PET imaging tracers, and CSF diagnostics
Therapeutic Pipeline: Update on monoclonal antibodies, small molecules, gene therapies, and combinatorial approaches
Prevention Strategies: Lifestyle interventions, cardiovascular risk modification, and early intervention approaches
Keynote Presentations
The conference featured several notable keynote addresses covering:
Precision Medicine in Alzheimer's: Dr. Reisa Sperling (Harvard Medical School) presented on biomarker-guided therapeutic approaches and the shift toward preclinical intervention
Neuroimmune Pathways: Dr. Michael Heneka (University of Bonn) discussed inflammasome activation and microglial modulation strategies
Single-Cell Genomics: Dr. Li-Huei Tsai (MIT) presented single-nucleus transcriptomics findings from human brain tissue
Global Dementia Prevention: Dr. Gill Livingston (UCL) reviewed modifiable risk factors and implementation strategies
Session Tracks
Basic Science Track
The basic science track covered fundamental mechanisms of neurodegeneration:
Molecular Mechanisms of Neurodegeneration
Amyloid-beta oligomerization pathways and toxicity mechanisms
Tau seed propagation and prion-like spreading
Alpha-synuclein aggregation in Lewy body disease
TDP-43 pathology in frontotemporal dementia and ALS
Protein Aggregation and Clearance
Autophagy-lysosomal pathway dysfunction
Ubiquitin-proteasome system impairment
ER stress and unfolded protein response
Chaperone-mediated protein homeostasis
Synaptic Dysfunction and Plasticity
Synaptic vesicle cycle alterations
NMDA receptor signaling abnormalities
Dendritic spine loss mechanisms
Network connectivity disruption
Genetic Risk Factors
APOE ε4 carrier status and risk modification
TREM2 coding variants and microglial function
Rare variant discovery in early-onset AD
Polygenic risk score applications
Glial Biology
Microglia: TREM2 biology, DAM phenotypes, complement system activation
Astrocytes: Reactive astrogliosis, metabolic support loss, glutamate homeostasis
Oligodendrocytes: Myelin degradation, white matter vulnerability
Neuroimmune Pathways
Inflammasome activation (NLRP3, AIM2)
Cytokine signaling (IL-1β, IL-6, TNF-α)
Complement system involvement in synapse elimination
T cell infiltration and peripheral immune crosstalk
Clinical Research Track
The clinical research track addressed translational and clinical aspects: